Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing regimens.

  • 0 views
  • 24 Jan, 2021
  • 21 locations
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by

  • 0 views
  • 27 Jan, 2021
  • 19 locations
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

therapy by Brentuximab Vedotin (BV) for up to one year. The primary objective of the trial is to show efficacy of the experimental consolidative treatment strategy. Secondary objectives are to

  • 0 views
  • 26 Jan, 2021
  • 1 location
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs

rituximab
measurable disease
avid
b-cell lymphoma
brentuximab
  • 0 views
  • 05 May, 2021
  • 37 locations
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic

positron emission tomography/computed tomography
combination chemotherapy
hysterectomy
dacarbazine
prednisone
  • 68 views
  • 05 May, 2021
  • 494 locations
Brentuximab Vedotin for Systemic Sclerosis

There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin

diffuse cutaneous systemic sclerosis
raynaud's phenomenon
methotrexate
MRSS
azathioprine
  • 710 views
  • 18 Apr, 2021
  • 10 locations
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

The trial assess the maximum tolerated dose of a single-dose of Brentuximab Vedotin added to standard BeEAM chemotherapy (comprising Bendamustin, Etoposide, Cyclophosphamide and Melphalan

remission
solid tumor
cell transplantation
cyclophosphamide
platelet count
  • 4 views
  • 26 Jan, 2021
  • 1 location
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis

The purpose of this study is to assess feasibility, safety and preliminary efficacy of Brentuximab vedotin (Adcetris), a CD30-directed antibody-drug conjugate, in the treatment of active diffuse

  • 63 views
  • 22 Apr, 2021
  • 1 location
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony

white blood cell count
graft versus host disease
measurable disease
brentuximab
dacarbazine
  • 44 views
  • 05 May, 2021
  • 51 locations
Dosing of Brentuximab Vedotin for Mycosis Fungoides Sezary Syndrome Patients

The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.

mycosis fungoides and sezary syndrome
systemic steroids
immunomodulator
brentuximab
prednisone
  • 24 views
  • 27 Jan, 2021
  • 9 locations